Description
Roche AVENIO Tumor Tissue Targeted Kits enable monitoring tumor burden in lung and colorectal cancer over time, as well as to assess for minimal residual disease.
Next-generation sequencing (NGS) liquid biopsy assay specially designed to monitor tumor burden in lung and colorectal cancer over time, as well as to assess for minimal residual disease (MRD). Contains 471 frequently mutated regions associated with the presence of disease across 197 genes.
Roche AVENIO Tumor Tissue Targeted Kits enable monitoring tumor burden in lung and colorectal cancer over time, as well as to assess for minimal residual disease.
SKU numbers, KK numbers, and product names